Brief: New England Journal Of Medicine Publishes Positive Phase 3 Valor Trial Results Of Brepocitinib In Dermatomyositis
28/03/2026 19:26
March 28 (Reuters) - Roivant Sciences Ltd ROIV.O: NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES POSITIVE PHASE 3 VALOR TRIAL RESULTS OF BREPOCITINIB IN DERMATOMYOSITIS ROIVANT SCIENCES LTD - FDA GRANTS PRIORITY REVIEW TO BREPOCITINIB NDA WITH PDUFA DATE IN Q3 2026 Source text: ID:nGNX5RjDP0 Further company coverage: ROIV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple